AZD 8421
Alternative Names: AZD-8421Latest Information Update: 23 Jun 2024
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Dec 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, United Kingdom, South Korea, Australia (PO) (NCT06188520)
- 05 Dec 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA, United Kingdom, South Korea, Australia (PO) (NCT06188520)